NCT04730349: A Study of Bempegaldesleukin (BEMPEG): NKTR-214 in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: up to 30 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes: Patients without brain metastasis are still eligible

Comments are closed.

Up ↑